Shares of Hims & Hers Health (NYSE:HIMS) climbed ~36% in the premarket on Tuesday after the telehealth company announced a partnership with Novo Nordisk (NVO) to sell the Danish drugmaker’s ...

While the new commercial will seek a national digital audience, having a Chicago player in a starring role may help drive ...

Hims & Hers has shown explosive growth, with potential revenue of $2.5B in FY25, trading at a low 2.4x FY25 sales. Despite the high short interest and bear arguments, HIMS' data-driven ...

Amla, or Indian gooseberry, is highlighted as a potent Ayurvedic remedy for hair regrowth, particularly for bald patches. Its rich Vitamin C, antioxidants, and essential fatty acids rejuvenate the ...

Shares of Hims & Hers Health (NYSE: HIMS) and LifeMD (NASDAQ: LFMD) are surging on Tuesday. The companie' stocks had jumped 24% and 34%, respectively, as of 3:15 p.m. ET as the S&P 500 and the ...

Hims & Hers Health, LifeMD, Ro, and other platforms like them will now be able to sell Novo Nordisk's Wegovy, which is used for weight loss. The blockbuster GLP-1 should entice customers. Shares ...

Hims & Hers Health is up 37.8% since the beginning of the year, but at $34.72 per share, it is still trading 49.5% below its 52-week high of $68.74 from February 2025.

Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk. The bundle will offer Novo ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the ...

Shelby Knowles / Bloomberg / Getty Images Hims & Hers Health shares surged Tuesday as the company announced a partnership with Danish drugmaker Novo Nordisk. Hims & Hers users will have access to ...